KR890006218A - 심장혈관계 질병치료용 투약기 - Google Patents
심장혈관계 질병치료용 투약기 Download PDFInfo
- Publication number
- KR890006218A KR890006218A KR1019880012536A KR880012536A KR890006218A KR 890006218 A KR890006218 A KR 890006218A KR 1019880012536 A KR1019880012536 A KR 1019880012536A KR 880012536 A KR880012536 A KR 880012536A KR 890006218 A KR890006218 A KR 890006218A
- Authority
- KR
- South Korea
- Prior art keywords
- osmotic
- component
- molecular weight
- izradipine
- dosage
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims 20
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 온혈동물의 위장관 이즈라디핀 수용체로 구강을 통하여 이즈라디핀을 투약하도록 하는데 적합하며 그에 따르는 형태를 하는 투약기.
제2도는 투약기의 내부구조를 설명하는 제1도 투약기의 개방도.
제3도는 투약기로부터 일정기간동안 시간마다 방출되는 이즈라디핀의 투약량을 도시한 그래프.
제4도는 32시간까지 연장된 시간동안 투약기에 의해 투약되는 이즈라디핀의 축적된 양을 도시한 그래프.
Claims (13)
- 효과가 있을 생물학적 체내 환경부위로 이즈라디핀을 투약하기 위한 심투성 투약기에 있어서, (A)이즈라디핀의 투약량과 분자량이 약 200,000인 폴리에틸렌 산화물을 포함하는 제1성분, (B)약 5,000,000 내지 7,800,000의 분자량을 갖는 폴리에틸렌 산화물 포함의 제2성분, (C)적어도 부분적으로는 사용중인 체내 환경내에 존재하는 외부유체의 통과에 대해 침투성이 있는 성분을 포함하는 벽을 포함하여, 이같은 벽이 제1 및 제2 성분을 둘러싸고, 그리고 (D)사용중인 환경으로 이즈라디핀을 전달시키기 위해 투약제의 외부를 투약제의 내부와 연결시키는 적어도 하나의 통로를 벽내에 포함함을 특징으로 하는 투약기.
- 제1항에 있어서, 제1 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로즈를 포함함을 특징으로 하는 삼투성 투약기.
- 제1항에 있어서, 제2 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
- 제1항에 있어서, 제2 성분이 오즈마전트(osmagent)를 포함함을 특징으로 하는 삼투성 투약기.
- 효과가 있는 생물학적 체내 환경부위로 이즈라디핀을 투약하기 위한 삼투성 투약기에 있어서, (A)이즈라디핀의 투약량과 분자량이 약 300,000인 톨리에틸렌 산화물을 포함하는 제1성분, (B)약 5,000,000 내지 7,800,000의 분자량을 갖는 폴리에틸렌 산화물 포함의 제2성분, (C)적어도 부분적으로는 사용중인 체내 환경내에 존재하는 외부유체의 통과에 대해 침투성이 있는 성분을 포함하는 벽을 포함하여, 이같은 벽이 제1 및 제2 성분을 둘러싸고, 그리고 (D)사용중인 환경으로 이즈라디핀을 전달시키기 위해 투약제의 외부를 투약재의 내부와 연결시키는 적어도 하나의 통로를 벽내에 포함함을 특징으로 하는 투약기.
- 제5항에 있어서, 제1 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
- 제5항에 있어서, 제2 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
- 제5항에 있어서, 제2 성분이 삼투압에 의해 영향을 받는 용질을 포함함을 특징으로 하는 삼투성 투약기. 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
- 온혈동물로 이즈라디핀을 투약하기 위한 삼투성 투약기에 있어서, (A)이즈라디핀, 분자량이 약 200,000인 톨리에틸렌 산화물, 그리고 분자량이 약 300,000인 폴리에틸렌 산화물 포함의 제1 가로막(얇은층), (B)분자량이 약 5,000,000 내지 7,800,000인 폴리에틸렌 산화물 포함의 제2가로막, (C)제1성분과 제2성분을 둘러싸며, 유체통과에 대하여 적어도 부분적으로 침투가 가능한 성분을 포함하는 벽, 그리고 (D)온혈동물로 이즈라디핀을 전달시키기 위해 벽내에 적어도 하나의 출구수단을 포함함을 특징으로 하는 삼투성 투약기.
- 제9항에 있어서, 제1가로막이 하이드록시프로필 메틸셀쿨로우즈를 포함함을 특징으로 하는 삼투성 투약제.
- 제9항에 있어서, 제2가로막이 하이드록시프로필 메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약제.
- 제9항에 있어서, 제2가로막이 삼투압에 의해 영향을 받는 화합물을 포함함을 특징으로 하는 삼투성 투약제.
- 단위시간당 측정된 방출속도로 약제를 투약하기 위한 삼투성 기구에 있어서, (A)유체의 통과에 대해 적어도 일부가 침투가 가능한 성분으로 되어 있는 벽을 포함하고, 이때의 벽이 (B)격실, (C)격실내에 존재하는 약제를 삼투성 기구로부터 전달시키기 위해 삼투성기구의 외부를 격실과 연결시키기 위한 벽내의 출구수단을 둘러싸고 이들을 형성시키는 것으로서, (D)상기에서와 같은 격실내에 폴리에틸렌 산화물을 포함하며, 폴리에틸렌 산화물이 약 5,000,000 내지 7,800,000의 분자량을 갖고, 단위시간당 측정된 방출속도로 약제를 투약시키기 위해 삼투성 기구와 형동하기 위한 수단임을 특징으로 하는 삼투성 기구.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US104,006 | 1987-10-02 | ||
US07/104,006 | 1987-10-02 | ||
US07/104,006 US4816263A (en) | 1987-10-02 | 1987-10-02 | Dosage form for treating cardiovascular diseases comprising isradipine |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890006218A true KR890006218A (ko) | 1989-06-12 |
KR950010151B1 KR950010151B1 (ko) | 1995-09-11 |
Family
ID=22298196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880012536A KR950010151B1 (ko) | 1987-10-02 | 1988-09-28 | 개량된 이즈라디핀 투약제 |
Country Status (22)
Country | Link |
---|---|
US (1) | US4816263A (ko) |
JP (1) | JP2590235B2 (ko) |
KR (1) | KR950010151B1 (ko) |
AT (1) | AT402689B (ko) |
AU (1) | AU615215B2 (ko) |
BE (1) | BE1001101A5 (ko) |
CA (1) | CA1317550C (ko) |
CH (1) | CH677609A5 (ko) |
DE (1) | DE3833282C2 (ko) |
DK (1) | DK175564B1 (ko) |
ES (1) | ES2011120A6 (ko) |
FI (1) | FI92554C (ko) |
FR (1) | FR2622798B1 (ko) |
GB (1) | GB2210266B (ko) |
IE (1) | IE61862B1 (ko) |
IT (1) | IT1234215B (ko) |
LU (1) | LU87351A1 (ko) |
NL (1) | NL194748C (ko) |
NO (1) | NO176466C (ko) |
PT (1) | PT88618B (ko) |
SE (1) | SE503471C2 (ko) |
ZA (1) | ZA887362B (ko) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946687A (en) * | 1987-10-02 | 1990-08-07 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
US6124355A (en) * | 1995-05-22 | 2000-09-26 | Guittard; George V. | Oxybutynin therapy |
US20040062799A1 (en) * | 1997-09-29 | 2004-04-01 | Ayer Atul D. | Therapeutic composition and delivery system for administering drug |
DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
US20010038855A1 (en) * | 1998-06-05 | 2001-11-08 | Desjardin Michael A. | Dosage form for administering prescribed dose |
US6238697B1 (en) | 1998-12-21 | 2001-05-29 | Pharmalogix, Inc. | Methods and formulations for making bupropion hydrochloride tablets using direct compression |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1404324B2 (en) * | 2001-06-11 | 2011-04-06 | XenoPort, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
JP2005501013A (ja) * | 2001-06-11 | 2005-01-13 | ゼノポート,インコーポレイテッド | Gaba類似体の全身濃度が持続するアミノ酸コンジュゲート |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US6524618B1 (en) | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
AU2003293423A1 (en) | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
WO2004053192A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
EP1608357A4 (en) * | 2003-03-31 | 2008-03-26 | Xenoport Inc | TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE |
PT1660440E (pt) * | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
EP2354120A1 (en) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
US7700652B2 (en) * | 2003-09-11 | 2010-04-20 | Xenoport, Inc. | Treating urinary incontinence using prodrugs of GABA analogs |
EP1677812A4 (en) * | 2003-09-17 | 2010-03-24 | Xenoport Inc | TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS |
US20060128676A1 (en) * | 2004-07-13 | 2006-06-15 | Pharmacofore, Inc. | Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain |
US7566738B2 (en) * | 2004-11-03 | 2009-07-28 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
US7494985B2 (en) * | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
CN101068538A (zh) * | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
EP1919859B1 (en) * | 2005-06-20 | 2010-06-02 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid and use |
WO2007002597A2 (en) | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
US20070049626A1 (en) * | 2005-08-26 | 2007-03-01 | Tran Pierre V | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
US20070128282A1 (en) * | 2005-12-02 | 2007-06-07 | Patel Hasmukh B | Oral osmotic drug delivery system |
DK2046393T3 (da) | 2006-05-26 | 2014-05-12 | Signature Therapeutics Inc | Kontrolleret frigivelse af phenol-opioider |
WO2008033572A1 (en) * | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
MX2009006080A (es) * | 2006-12-08 | 2009-07-14 | Xenoport Inc | Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades. |
US7714201B2 (en) * | 2006-12-22 | 2010-05-11 | Monsanto Technology Llc | Cotton variety 781000G |
US7419684B2 (en) * | 2006-12-22 | 2008-09-02 | Reliant Pharmaceuticals, Inc. | System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same |
WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
WO2012050907A2 (en) | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
CN102349880B (zh) * | 2011-10-12 | 2015-07-22 | 合肥华方医药科技有限公司 | 伊拉地平控释片及其制备方法 |
CN105030726A (zh) * | 2015-08-30 | 2015-11-11 | 四川百利药业有限责任公司 | 一种伊拉地平胶囊的制备方法 |
US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
US9808452B2 (en) | 2015-10-01 | 2017-11-07 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
CA3056239C (en) | 2017-03-17 | 2023-09-12 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
CH639659A5 (de) * | 1978-12-18 | 1983-11-30 | Sandoz Ag | Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung. |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
NZ206600A (en) * | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
GB2181053B (en) * | 1985-10-01 | 1990-05-23 | Sandoz Ltd | Pharmaceutical formulations with controlled release of the active substance |
US4723957A (en) * | 1986-02-07 | 1988-02-09 | Alza Corp. | System for delivering drug with enhanced bioacceptability |
US4753802A (en) * | 1986-03-19 | 1988-06-28 | Alza Corporation | Verapamil dosage form |
AU2152888A (en) * | 1987-08-25 | 1989-03-02 | Cerra Metal Works Pty. Ltd. | Masonry tie |
US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
-
1987
- 1987-10-02 US US07/104,006 patent/US4816263A/en not_active Expired - Lifetime
-
1988
- 1988-09-27 BE BE8801099A patent/BE1001101A5/fr not_active IP Right Cessation
- 1988-09-27 NO NO884259A patent/NO176466C/no not_active IP Right Cessation
- 1988-09-28 LU LU87351A patent/LU87351A1/fr unknown
- 1988-09-28 KR KR1019880012536A patent/KR950010151B1/ko not_active IP Right Cessation
- 1988-09-29 NL NL8802401A patent/NL194748C/nl not_active IP Right Cessation
- 1988-09-29 FR FR8812738A patent/FR2622798B1/fr not_active Expired - Lifetime
- 1988-09-29 AU AU22938/88A patent/AU615215B2/en not_active Expired
- 1988-09-29 GB GB8822852A patent/GB2210266B/en not_active Expired - Lifetime
- 1988-09-29 DK DK198805450A patent/DK175564B1/da active
- 1988-09-29 PT PT88618A patent/PT88618B/pt not_active IP Right Cessation
- 1988-09-30 DE DE3833282A patent/DE3833282C2/de not_active Expired - Lifetime
- 1988-09-30 SE SE8803486A patent/SE503471C2/sv not_active IP Right Cessation
- 1988-09-30 IE IE296088A patent/IE61862B1/en not_active IP Right Cessation
- 1988-09-30 CA CA000578959A patent/CA1317550C/en not_active Expired - Lifetime
- 1988-09-30 FI FI884526A patent/FI92554C/fi not_active IP Right Cessation
- 1988-09-30 ZA ZA887362A patent/ZA887362B/xx unknown
- 1988-09-30 CH CH3642/88A patent/CH677609A5/de not_active IP Right Cessation
- 1988-09-30 ES ES8802980A patent/ES2011120A6/es not_active Expired
- 1988-09-30 IT IT8867880A patent/IT1234215B/it active
- 1988-09-30 JP JP63247298A patent/JP2590235B2/ja not_active Expired - Lifetime
- 1988-09-30 AT AT0242288A patent/AT402689B/de not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890006218A (ko) | 심장혈관계 질병치료용 투약기 | |
KR880013586A (ko) | 고체상태성질을 가진 제거 가능한 기질을 포함하는 투약기 | |
US4693886A (en) | Osmotic device with inert core | |
TW446552B (en) | Osmotic delivery system with membrane plug retention mechanism | |
FI107699B (fi) | Annostusmuoto lääkkeen annostelun ajan suhteen vaihtelevien mallien aikaansaamiseksi | |
US4210139A (en) | Osmotic device with compartment for governing concentration of agent dispensed from device | |
NL193308C (nl) | Doseervorm geschikt voor de afgifte van een preparaat van een heilzaam middel aan een gebruiksomgeving. | |
JP3301612B2 (ja) | ローディングドースを含む長期配送デバイス | |
US5147654A (en) | Oral osmotic device for delivering nicotine | |
US4474575A (en) | Self-driven pump assembly and method of operation | |
KR870008583A (ko) | 슈도에페드린, 브롬페니라민 요법 | |
JP2773857B2 (ja) | 結腸放出系浸透圧構成体 | |
KR920703020A (ko) | 히드로겔 드라이빙 부재를 갖는 구강 삼투 장치 | |
KR920703066A (ko) | 경구용 혈당강하제인 글리피자이드의 투여를 위한 제형 | |
KR890000081A (ko) | O차 조절된 약물 전달 시스템 | |
KR890004684A (ko) | 신속 방출제 전달계와 완속 방출제 전달계로 된 제형(劑刑) | |
NO923756L (no) | Osmotisk doseringssystem for avgivelse av vaeskeformig medikament | |
PT96152A (pt) | Sistema de libertacao pulsatil multi-unitario | |
MX2012000502A (es) | Capsulas de liberacion sostenida. | |
KR870008594A (ko) | 베라파밀제형 | |
CA2047418A1 (en) | Oral osmotic device for delivering nicotine | |
KR920703022A (ko) | 가용성 또는 불용성 약물의 전달을 위한 제형 | |
JPS6244249A (ja) | 有効剤組成物を反芻動物に投与するための投与デイバイス | |
JP3399527B2 (ja) | 疎水性装填薬剤を含む長期的投与デイバイス | |
US20060043207A1 (en) | Apparatus, kit and related methods for administering substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20020903 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |